Who Exports Simvastatin from India — 150 Suppliers Behind a $125.9M Market
India's simvastatin export market is supplied by 150 active exporters who collectively shipped $125.9M across 3,854 shipments. MYLAN LABORATORIES LIMITED leads with a 25.4% market share, followed by LUPIN LIMITED and IPCA LABORATORIES LIMITED. The top 5 suppliers together control 72.5% of total export value, reflecting a concentrated market structure.
Top Simvastatin Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading simvastatin exporter from India, holding a 25.4% share of the $125.9M market across 3,854 shipments from 150 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, LUPIN LIMITED, IPCA LABORATORIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, AUROBINDO PHARMA LTD — collectively control 72.5% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (25.4%), LUPIN LIMITED (20.1%), IPCA LABORATORIES LIMITED (12.0%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (8.2%), AUROBINDO PHARMA LTD (6.8%).
Top Simvastatin Exporters from India
Ranked by export value · 150 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED SIMVASTATIN TABLETS 10MGSIMVASTATIN TABLETS 20MG ( SIMVA BASICSSIMVASTATIN TABLETS 40MG ( SIMVA BASICS | $31.9M | 8 | 25.4% |
| 2 | LUPIN LIMITED SIMVASTATIN 40 MG TABLETS 1000'S PACKSIMVASTATIN TABLETS USP 40MG US R1 SISIMVASTATIN TABLET | $25.3M | 1 | 20.1% |
| 3 | IPCA LABORATORIES LIMITED SIMVASTATIN 40MG TABLETS[EACH TAB CONT:SIMVASTATINHARMLESS MEDICINES:SIMVASTATIN 20MG TABLETS[EACH TAHARMLESS MEDICINES:SIMVASTATIN TABLETS 4 | $15.1M | 6 | 12.0% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED SIMVASTATIN TABLETS 20MG ( SIMVA BASICSSIMVASTATIN TABLETS 40MG ( SIMVA BASICSSIMVASTATIN 40 MG TABLETS 1000'S PACK | $10.4M | 5 | 8.2% |
| 5 | AUROBINDO PHARMA LTD SIMVASTATIN 10MG TABLETS(SIMVASTATINA AUSIMVASTATIN 40 MG TABLETS 1000'S PACKSIMVASTATIN TABLETS 20MG(SIMVASTATINA AU | $8.5M | 7 | 6.8% |
| 6 | HETERO LABS LIMITED SIMVASTATIN 40 MG TABLETS 1000'S PACKSIMVASTATIN TABLETS USP 40MG US R1 SISIMVASTATIN TABLET | $7.1M | 3 | 5.6% |
| 7 | AUROBINDO PHARMA LIMITED SIMVASTATIN 10MG TABLETS(SIMVASTATINA AUSIMVASTATIN 40 MG TABLETS 1000'S PACKSIMVASTATIN TABLETS 20MG(SIMVASTATINA AU | $3.3M | 8 | 2.6% |
| 8 | FREDUN PHARMACEUTICALS LTD SIMVASYN 40 - SIMVASTATIN 40MG FILM-COATED TABLETSIMVASTATIN 20 MG FILM COATED TABLET | $2.6M | 1 | 2.1% |
| 9 | INTAS PHARMACEUTICALS LIMITED SIMVASTATIN 10MG TABLETS 273969 X 2 X 14SIMVASTATIN 40MG FILM COATED TABLETS(2X1 | $2.4M | 6 | 1.9% |
| 10 | TORRENT PHARMACEUTICALS LTD SIMVASTATIN 10MG TABLETS(SIMVASTATINA AUSIMVASTATIN TABLETS 20MG(SIMVASTATINA AUSIMVASTATIN TABLETS 20MG(SINVASTATINA AU | $2.3M | 8 | 1.9% |
| 11 | QUALIGENS PHARMA PRIVATE LIMITED | $2.1M | 1 | 1.7% |
| 12 | MEPRO PHARMACEUTICALS PRIVATE LIMITED | $2.0M | 5 | 1.6% |
| 13 | ALKEM LABORATORIES LIMITED SIMVASTATIN 40 MG TABLETS 1000'S PACKSIMVASTATIN TABLETS USP 40MG US R1 SISIMVASTATIN TABLET | $1.9M | 4 | 1.5% |
| 14 | CIPLA LIMITED SIMVAR 80 TABLETOTHERS : APO-EZETIMIBE/SIMVASTATIN 10/80SIMVASTATIN TABLETS 80 MG PACKS 8500'SBSP | $1.6M | 4 | 1.3% |
| 15 | WATSON PHARMA PRIVATE LIMITED SIMVASTATIN 10MG TABLETS(SIMVASTATINA AUSIMVASTATIN 40 MG TABLETS 1000'S PACKSIMVASTATIN TABLETS 20MG(SIMVASTATINA AU | $1.1M | 3 | 0.9% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Simvastatin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| LUPIN LIMITED | Approved | Yes | Yes | Multiple | Lupin has received multiple FDA approvals, including for Chlorpromazine Hydrochl |
| AUROBINDO PHARMA LIMITED | Approved | Yes | Yes | Multiple | Aurobindo received an FDA warning letter in June 2019 for its Pydibhimavaram fac |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Mylan's Indore facility received an FDA warning letter in December 2024. (extran |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Intas received EU GMP certification in April 2007 for its biosimilar Filgrastim. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | Multiple | Sun Pharma is a leading pharmaceutical company with multiple FDA approvals. |
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla has a strong presence in the pharmaceutical industry with multiple FDA app |
| TORRENT PHARMACEUTICALS LTD | Approved | Yes | Yes | Multiple | Torrent Pharmaceuticals has received multiple FDA approvals. |
| HETERO LABS LIMITED | Approved | Yes | Yes | Multiple | Hetero Labs has a significant presence in the pharmaceutical industry with multi |
| IPCA LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | IPCA Laboratories has received multiple FDA approvals. |
| ALKEM LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Alkem Laboratories has a strong presence in the pharmaceutical industry with mul |
TransData Nexus reviewed the regulatory standing of 10 leading Simvastatin exporters from India. 10 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Simvastatin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy's Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in research and development. This robust infrastructure makes Hyderabad a critical center for API manufacturing, which is essential for the production of drugs like Simvastatin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to major companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's well-developed infrastructure, including ports and transportation networks, supports efficient manufacturing and distribution of finished pharmaceutical products, including Simvastatin tablets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a significant export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, hosts numerous pharmaceutical companies with a strong focus on both domestic and international markets. The region's proximity to major ports facilitates the export of pharmaceutical products, including Simvastatin, to various countries. Companies like Cipla, headquartered in Mumbai, leverage this strategic location to enhance their global reach.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, has emerged as a prominent pharmaceutical manufacturing hub, partly due to favorable tax incentives offered by the government. The region houses over 1,000 pharmaceutical manufacturing units, making it one of the largest pharmaceutical hubs in Asia. Companies such as Cipla and Dr. Reddy's Laboratories have established significant operations in Baddi, contributing to its reputation as a key player in the production of various pharmaceutical products, including Simvastatin.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 72.5% of Simvastatin shipments, it's advisable to diversify sourcing to mitigate risks associated with supplier concentration.
- Leverage Regional Strengths: Utilize Hyderabad for API procurement and Ahmedabad-Vadodara for formulations to capitalize on regional specializations.
- Evaluate Export Logistics: Consider Mumbai-Thane-Raigad for export operations due to its proximity to major ports, facilitating efficient international distribution.
- Assess Cost Benefits: Explore manufacturing options in Baddi-Nalagarh to take advantage of potential tax incentives and cost-effective production capabilities.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Simvastatin exporters from India
Lupin Limited — Lupin partners with PolyPeptide Group for peptide APIs
Lupin Manufacturing Solutions entered into a long-term agreement with PolyPeptide Group AG to supply peptide active pharmaceutical ingredients (APIs). - IMPACT: This collaboration is expected to enhance Lupin's API portfolio, potentially increasing Simvastatin production capacity.
Impact: This collaboration is expected to enhance Lupin's API portfolio, potentially increasing Simvastatin production capacity.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma finalized a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. - IMPACT: This acquisition may bolster Sun Pharma's manufacturing capabilities, potentially affecting Simvastatin export volumes.
Impact: This acquisition may bolster Sun Pharma's manufacturing capabilities, potentially affecting Simvastatin export volumes.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma acquired Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: This acquisition is likely to diversify Sun Pharma's product portfolio, with potential implications for Simvastatin production and exports.
Impact: This acquisition is likely to diversify Sun Pharma's product portfolio, with potential implications for Simvastatin production and exports.
Common Questions — Simvastatin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which simvastatin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 265 recorded shipments worth $31.9M. LUPIN LIMITED (416 shipments) and IPCA LABORATORIES LIMITED (77 shipments) are also established high-volume exporters.
Q How many simvastatin manufacturers are there in India?
India has 150 active simvastatin exporters with a combined export market of $125.9M across 3,854 shipments to 84 countries. The top 5 suppliers hold 72.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for simvastatin from India?
Average FOB unit price: $39.96 per unit, ranging from $0.00 to $37014.19. Average shipment value: $32.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 150 verified Indian exporters of Simvastatin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,854 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 84 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,854 Verified Shipments
150 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists